Chemed Corporation $CHE Stock Bought by Boston Partners

Chemed logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Partners increased its Chemed stake by 34.3% in the third quarter, buying 96,311 shares and bringing its holdings to 376,995 shares, worth about $190.4 million. Institutional investors collectively own 95.85% of the company.
  • Chemed reported quarterly adjusted earnings of $6.75 per share, beating estimates of $6.44, while revenue rose 10.6% year over year to $690.94 million. The company also declared a $0.70 quarterly dividend.
  • Analysts’ consensus rating was Hold, with an average price target of $603; Jefferies upgraded the stock to Buy, while executives reported selling shares in the quarter.
  • Five stocks we like better than Chemed.

Boston Partners boosted its stake in shares of Chemed Corporation (NYSE:CHE - Free Report) by 34.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 376,995 shares of the company's stock after buying an additional 96,311 shares during the quarter. Boston Partners owned approximately 2.90% of Chemed worth $190,416,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of CHE. BlackRock Inc. acquired a new position in shares of Chemed in the second quarter worth about $691,290,000. First Trust Advisors LP increased its stake in shares of Chemed by 24.7% in the first quarter. First Trust Advisors LP now owns 236,392 shares of the company's stock worth $89,295,000 after buying an additional 46,791 shares during the last quarter. Copeland Capital Management LLC raised its holdings in shares of Chemed by 1.3% in the 3rd quarter. Copeland Capital Management LLC now owns 146,833 shares of the company's stock worth $74,162,000 after purchasing an additional 1,826 shares in the last quarter. Bank of America Corp DE bought a new position in Chemed during the second quarter valued at about $48,255,000. Finally, Caisse de depot et placement du Quebec bought a new stake in shares of Chemed in the 2nd quarter valued at approximately $44,309,000. Hedge funds and other institutional investors own 95.85% of the company's stock.

Chemed Stock Up 0.9%

Shares of CHE opened at $551.41 on Friday. The company has a market capitalization of $7.18 billion, a price-to-earnings ratio of 26.38, a PEG ratio of 2.08 and a beta of 0.50. The stock's 50-day moving average price is $519.43 and its 200-day moving average price is $469.94. Chemed Corporation has a 52 week low of $365.20 and a 52 week high of $562.24. The company has a quick ratio of 1.08, a current ratio of 1.11 and a debt-to-equity ratio of 0.27.

Chemed (NYSE:CHE - Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported $6.75 EPS for the quarter, topping the consensus estimate of $6.44 by $0.31. Chemed had a return on equity of 35.18% and a net margin of 10.61%. The firm had revenue of $690.94 million during the quarter, compared to analysts' expectations of $685.04 million. During the same period in the previous year, the firm posted $5.27 EPS. Chemed's revenue for the quarter was up 10.6% on a year-over-year basis. On average, sell-side analysts predict that Chemed Corporation will post 24.05 EPS for the current year.

Chemed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 4th. Stockholders of record on Monday, November 16th will be given a dividend of $0.70 per share. The ex-dividend date is Monday, November 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. Chemed's payout ratio is currently 13.40%.

Analyst Ratings Changes

Several analysts have recently weighed in on CHE shares. Bank of America restated a "neutral" rating on shares of Chemed in a report on Wednesday, July 29th. Jefferies Financial Group raised Chemed from a "hold" rating to a "buy" rating and increased their price target for the stock from $520.00 to $620.00 in a research report on Wednesday, October 28th. Weiss Ratings raised Chemed from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Royal Bank Of Canada increased their price target on shares of Chemed from $548.00 to $585.00 and gave the company a "sector perform" rating in a research note on Thursday, October 29th. Finally, Oppenheimer increased their price target on shares of Chemed from $590.00 to $625.00 and gave the stock an "outperform" rating in a research note on Thursday, October 29th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $603.00.

Read Our Latest Stock Analysis on CHE

Insider Buying and Selling

In related news, CEO Kevin McNamara sold 2,000 shares of the business's stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the completion of the sale, the chief executive officer directly owned 66,418 shares of the company's stock, valued at $34,102,322.10. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Spencer Lee sold 1,000 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $547.61, for a total transaction of $547,610.00. Following the transaction, the executive vice president owned 12,931 shares of the company's stock, valued at $7,081,144.91. The trade was a 7.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 7,920 shares of company stock valued at $4,147,306 in the last quarter. 3.33% of the stock is currently owned by corporate insiders.

Chemed Profile

(Free Report)

Chemed Corporation is a U.S.-based company operating through two principal businesses: VITAS Healthcare, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing, drain-cleaning and water-restoration services. VITAS serves patients with serious illnesses through home-based care and services in hospice facilities and other care settings. Roto-Rooter serves residential and commercial customers with plumbing and drain services, as well as cleanup and restoration following water damage.

Featured Stories

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Chemed Right Now?

Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines